CCL22 and hepatocellular carcinoma: Considering the crucial effect of SOX12‐CCL22/CCR4 and SOX12‐PD‐L1 axis on the TIME remodeling and the HCC progression and metastasis, we evaluated the antitumor effect of combining CCR4 inhibitor (C‐021) with anti‐PD‐L1 in HCC models.